Table 2 Evaluation of the experimental formulation during 12 months of intervention and 6 months of follow up in WOMAC subscales

Pain

Baseline

5.8 (5.2, 6.4) ^a

5.6 (5.0, 6.2)

3 mo.

1.9 (1.1, 2.8) ^b

−4.0 (−7.0, −5.1)

2.4 (1.7, 3.2)

−3.2 (−3.9, −2.5)

8 mo.

1.6 (1.0, 2.2)

−4.2 (−9.1, −5.1)

1.5 (1.0, 2.0)

−4.0 (−4.9, −3.2)

12 mo.

1.1 (0.6, 1.7)

−4.5 (−10.5, −5.3)

1.3 (0.8, 1.9)

−4.5 (−5.2, −3.8)

18 mo.

1.2 (0.5, 1.9)

−4.3 (−8.4, −5.3)

1.0 (0.5, 1.5)

−4.8 (−5.6, −4.0)

Stiffness

Baseline

5.9 (5.0, 6.7)

6.3 (5.6, 7.0)

3 mo.

2.0 (1.3, 2.6)

−4.2 (−9.0, −5.1)

2.1 (1.3, 2.9)

−4.0 (−4.9, −3.2)

8 mo.

1.0 (0.5, 1.5)

−4.8 (−9.3, −5.8)

1.5 (0.9, 2.0)

−4.8 (−5.7, −3.8)

12 mo.

0.5 (0.2, 0.9)

−5.2 (−10.7, −6.2)

1.3 (0.6, 2.0)

−4.9 (−5.9, −4.0)

18 mo.

0.7 (0.0, 1.4)

−5.0 (−7.9, −6.3)

1.1 (0.4, 1.7)

−5.0 (−6.0, −4.0)

Physical functioning

Baseline

5.9 (5.2, 6.6)

6.2 (5.4, 6.9)

3 mo.

2.1 (1.5, 2.8)

−3.8 (−7.6, −4.9)

2.1 (1.5, 2.8)

−3.8 (−4.5, −3.1)

8 mo.

1.4 (0.9, 1.9)

−4.6 (−10.2, −5.5)

1.5 (1.1, 2.0)

−4.7 (−5.6, −3.9)

12 mo.

0.6 (0.4, 0.9)

−5.1 (−13.3, −5.9)

1.2 (0.6, 1.7)

−5.2 (−6.1, −4.3)

18 mo.

0.7 (0.3, 1.2)

−4.8 (−9.6, −5.9)

1.0 (0.5, 1.4)

−5.2 (−6.2, −4.3)

Global score

Baseline

17.5 (15.7, 19.3)

18.1 (16.3, 19.9)

3 mo.

6.0 (4.2, 7.9)

−11.9 (−9.1, −14.7)

6.7 (4.7, 8.7)

−11.1 (−13.1, −9.1)

8 mo.

4.2 (2.7, 5.6)

−13.5 (−10.4, −16.1)

4.5 (3.1, 5.9)

−13.6 (−15.9, −11.2)

12 mo.

2.3 (1.5, 3.1)

−14.8 (−14.2, −17.0)

3.8 (2.1, 5.5)

−14.6 (−16.9, −12.4)

18 mo.

2.6 (0.8, 4.4)

−14.0 (−9.7, −17.1)

3.1 (1.5, 4.6)

−15.0 (−17.5, −12.6)